GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » 10-Year RORE %

CanSino Biologics (HKSE:06185) 10-Year RORE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. CanSino Biologics does not have enough data to calculate 10-Year RORE %.


CanSino Biologics 10-Year RORE % Historical Data

The historical data trend for CanSino Biologics's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics 10-Year RORE % Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial - - - - -

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CanSino Biologics's 10-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's 10-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's 10-Year RORE % falls into.



CanSino Biologics 10-Year RORE % Calculation

CanSino Biologics's 10-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 10-year before.


CanSino Biologics  (HKSE:06185) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


CanSino Biologics 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (HKSE:06185) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
Executives
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Mao Helen Huihua 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Yu Xuefeng 2501 Other
Zhu Tao
Chao Shou Bai 2202 Interest of your spouse
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines